Sep 2, 2026, 4:17 PM ETHealthcare

Attovia Therapeutics — Second Quarter 2026 Earnings Summary

ATTOATTOVIA THERAPEUTICS INC

Financial Performance

Collaboration revenue for the quarter ended June 30, 2026, was $0.5 million, compared to $0 in the second quarter of 2025.
Research and development expenses were $18.9 million for the quarter ended June 30, 2026, an increase from $13.6 million in the second quarter of 2025.
General and administrative expenses were $3.3 million for the quarter ended June 30, 2026, compared to $3.0 million in the second quarter of 2025.
Net loss was $20.7 million for the quarter ended June 30, 2026, compared to $14.4 million in the second quarter of 2025.
Cash, cash equivalents, and marketable securities were $115.1 million as of June 30, 2026, down from $152.3 million as of December 31, 2025.
Total assets were $128.3 million as of June 30, 2026, compared to $165.9 million as of December 31, 2025.
Total liabilities were $15.6 million as of June 30, 2026, compared to $15.1 million as of December 31, 2025.
Total stockholders' deficit was $(145.5) million as of June 30, 2026, compared to $(107.4) million as of December 31, 2025.
Net loss per share attributable to common stockholders was $(4.88) for the quarter ended June 30, 2026, compared to $(3.71) in the second quarter of 2025.

The Company expects its current cash, cash equivalents, and marketable securities, including net proceeds from the August 2026 IPO of approximately $305.4 million, to fund operations into 2030.
Complete Phase 1b data for ATTO-1310 is expected in the fourth quarter of 2026.
Phase 2 studies for ATTO-1310 in chronic pruritus of unknown origin and high-itch atopic dermatitis are planned for the first half of 2027.
Phase 1 initiation for ATTO-2306 and ATTO-1091 is planned for the first half of 2027.
The Company aims to advance ATTO-006 toward development candidate nomination by year-end 2026.

ATTO-1310, an ATTOBODY-based Fc-fusion protein targeting IL-31, demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis, showing rapid, deep itch relief and consistent lesion control.
The Phase 1a study for ATTO-1310 in healthy volunteers showed favorable tolerability, rapid and sustained suppression of IL-31, and low immunogenicity.
The protocol for the global Phase 2 study of ATTO-1310 in chronic pruritus of unknown origin was submitted to the FDA after incorporating agency feedback on design elements and endpoints.
ATTO-2306, a bispecific antibody targeting IL-31 and IL-13, demonstrated highly potent inhibition of targets, long half-life, and low immunogenicity risk in preclinical studies.
ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7, demonstrated potent inhibition of all three targets and favorable developability properties in preclinical studies.
IND clearance was received for a Phase 1b trial of ATTO-1310 in patients with cholestatic pruritus associated with primary biliary cholangitis or primary sclerosing cholangitis in China via an expedited review pathway.
Collaboration revenue was generated under the EndPath RadioTherapeutics license agreement for research and development services.

The Company completed an upsized IPO with aggregate gross proceeds of approximately $332.4 million before deducting underwriting discounts and commissions.
Common stock now trades on the Nasdaq Global Market under the ticker symbol "ATTO".
John W. Smither was appointed to the Board of Directors as a proven financial leader with extensive public company board and audit committee experience.
The Company is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases using its internally discovered ATTOBODY biparatopic biologics platform.